Marwan Salfity, MD
Cardiovascular Disease · Omaha, NENPI 1053361824
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,309 of the $5,255 with a category attached, or 82.0%. 24 manufacturers reported payments, led by Boston Scientific at 26.0% of the total. Reporting peaked in 2024 at $1,422 and has fallen 71.2% since, to $409 in 2025.
Across 149 payments — averaging $35.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Abbott$646
- Johnson & Johnson$569
- Amgen$422
- Heartflow, Inc.$310
- Pfizer$292
- plus $2K from 18 others
What the payments were for
- Travel & lodging$94618%
- Food & beverage$4,30982%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 11 | $1,365 |
| Abbott | 6 | $646 |
| Johnson & Johnson | 17 | $569 |
| Amgen | 30 | $422 |
| Heartflow, Inc. | 3 | $310 |
| Pfizer | 11 | $292 |
| Amarin Pharma, Inc. | 11 | $278 |
| Novartis | 12 | $236 |
| Esperion Therapeutics, Inc. | 10 | $191 |
| AstraZeneca | 3 | $154 |
| E.r. Squibb & Sons, L.L.C. | 4 | $148 |
| Alnylam Pharmaceuticals Inc. | 2 | $148 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $86 |
| Janssen Scientific Affairs, LLC | 4 | $74 |
| Itamar Medical Inc | 1 | $62 |
| Actelion Pharmaceuticals US, Inc. | 4 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Merck | 3 | $48 |
| Lexicon Pharmaceuticals, Inc. | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Impulse Dynamics (USA) Inc. | 1 | $19 |
| Medtronic | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$1,126
- Quadra Assura CRT Defibrillator$295
- FFRct$277
- QUADRA ALLURE MP$148
- FARXIGA$125
- AMVUTTRA$125
- XARELTO$123
- Fortify Assura, Ellipse ICD$123
- Repatha$119
- VYNDAQEL$107
How this compares
$5,255 in reported general payments places this provider in the 70th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 844 | $746,575 |
| XareltoRivaroxaban | 274 | $268,066 |
| EntrestoSacubitril/Valsartan | 83 | $69,475 |
| Repatha SureclickEvolocumab | 39 | $24,532 |
| Repatha SyringeEvolocumab | 16 | $13,229 |
| Doxazosin Mesylate | 714 | $10,414 |
| Metoprolol Succinate | 974 | $9,775 |
| Amlodipine Besylate | 2,053 | $9,616 |
| VascepaIcosapent Ethyl | 15 | $9,273 |
| Ranolazine ErRanolazine | 95 | $7,514 |
| Losartan Potassium | 991 | $6,669 |
| Atorvastatin Calcium | 612 | $4,851 |
| Amiodarone Hcl | 434 | $4,522 |
| Carvedilol | 558 | $3,060 |
| Potassium Chloride | 177 | $2,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $292 | $746,575844 claims |
| Johnson & JohnsonXarelto | $569 | $268,066274 claims |
| NovartisEntresto | $236 | $69,47583 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Omaha
- Ronald ZoltyOmaha$945K
- Jeffrey CarstensOmaha$124K
- John HenryOmaha$79K
- Joseph ThibodeauOmaha$75K
- Qais RadaidehOmaha$50K
- Edward OlearyOmaha$36K
- Faris KhanOmaha$17K
- Michael PetersOmaha$13K
- Thomas PorterOmaha$11K
- Gregory PavlidesOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.